PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma

Journal of Clinical Oncology

Volumn 26, Issue 33, 2008, Pages 5443-5449

  Stutterheim, Janine ^a   Gerritsen, Annemieke ^a   Zappeij Kannegieter, Lily ^a   Kleijn, Ilona ^a   Dee, Rob ^a   Hooft, Lotty ^a   Van Noesel, Max M ^a   Bierings, Marc ^a   Berthold, Frank ^a   Versteeg, Rogier ^a   Caron, Huib N ^a   Van Der Schoot, C Ellen ^a   Tytgat, Godelieve A M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SYNTHETASE; TYROSINE 3 MONOOXYGENASE;

ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CONTROLLED STUDY; ENZYME ANALYSIS; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL; PHOX2B GENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; INFANT; MALE; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM, RESIDUAL; NERVE TISSUE PROTEINS; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE;

EID: 56749164899     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6531     Document Type: Article

References (40)

1. Cotterill SJ, Pearson AD, Pritchard J, et al: Clinical prognostic factors in 1277 patients with neuroblastoma: Results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 36:901-908, 2000
2. Hartmann O, Valteau-Couanet D, Vassal G, et al: Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 23:789-795, 1999
3. Cheung NK, Heller G, Kushner BH, et al: Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? J Clin Oncol 15:2807-2817, 1997
4. Mehes G, Luegmayr A, Kornmuller R, et al: Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol 163:393-399, 2003
5. Viprey VF, Corrias MV, Kagedal B, et al: Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 43:341-350, 2007
6. Mehes G, Luegmayr A, Ambros IM, et al: Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow. Clin Cancer Res 7:1969-1975, 2001
7. Lambooy LH, Gidding CE, van den Heuvel LP, et al: Real-time analysis of tyrosine hydroxylase gene expression: A sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res 9:812-819, 2003
8. Swerts K, De Moerloose B, Dhooge C, et al: Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells. Clin Chem 52:438-445, 2006
9. Martinez C, Hofmann TJ, Marino R, et al: Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 109:4245-4248, 5-15-2007
10. Horibe K, Fukuda M, Miyajima Y, et al: Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 36:203-204, 2001
11. Parareda A, Gallego S, Roma J, et al: Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma. Oncol Rep 14:1021-1027, 2005
12. Cheung IY, Cheung NK: Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 7:1698-1705, 2001
13. Hoon DS, Kuo CT, Wen S, et al: Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow. Am J Pathol 159:493-500, 2001
14. Ifversen MR, Kagedal B, Christensen LD, et al: Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 27:121-129, 2005
15. Kuci Z, Seitz G, Kuci S, et al: Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine- producing hematopoietic cells. Anticancer Res 26:2075-2080, 2006
16. Trager C, Kogner P, Lindskog M, et al: Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 49:104-112, 2003
17. Cheung IY, Cheung NK: Molecular detection of GAGE expression in peripheral blood and bone marrow: Utility as a tumor marker for neuroblastoma. Clin Cancer Res 3:821-826, 1997
18. Oltra S, Martinez F, Orellana C, et al: Minimal residual disease in neuroblastoma: To GAGE or not to GAGE. Oncol Res 14:291-295, 2004
19. Cheung IY, Barber D, Cheung NK: Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 4:2801-2805, 1998
20. Gilbert J, Norris MD, Marshall GM, et al: Low specificity of PGP9.5 expression for detection of micrometastatic neuroblastoma. Br J Cancer 75:1779-1781, 1997
21. Mattano LA, Jr., Moss TJ, Emerson SG: Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 52:4701-4705, 1992
22. Bozzi F, Luksch R, Collini P, et al: Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: Utility as a tumor marker for neuroblastoma. Diagn Mol Pathol 13:135-143, 2004
23. Cheung IY, Feng Y, Vickers A, et al: Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn 9:237-241, 2007
24. Cheung IY, Vickers A, Cheung NK: Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma. Int J Cancer 119:152-156, 2006
25. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993
26. Verhagen OJ, Willemse MJ, Breunis WB, et al: Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14:1426-1435, 2000
27. Swerts K, Ambros PF, Brouzes C, et al: Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 53:1433-1440, 2005
28. Beillard E, Pallisgaard N, van der Velden V, et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe Against Cancer program. Leukemia 17:2474-2486, 2003
29. van der Velden V, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604-611, 2007
30. Boon K, Caron HN, van Asperen R, et al: N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 20:1383-1393, 3-15-2001
31. Caron H, van Schaik B, van der MM, et al: The human transcriptome map: Clustering of highly expressed genes in chromosomal domains. Science 291:1289-1292, 2-16-2001
32. Beiske K, Ambros PF, Burchill SA, et al: Detecting minimal residual disease in neuroblastoma patients: The present state of the art. Cancer Lett 228:229-240, 10-18-2005
33. Reynolds CP: Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 8:56-66, 2004 (suppl 5)
34. Mosse YP, Laudenslager M, Khazi D, et al: Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet 75:727-730, 2004
35. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al: Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 74:761-764, 2004
36. van Limpt V, Schramm A, van Lakeman A, et al: The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23:9280-9288, 2004
37. Raabe EH, Laudenslager M, Winter C, et al: Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 27:469-476, 2008
38. Son CG, Bilke S, Davis S, et al: Database of mRNA gene expression profiles of multiple human organs. Genome Res 15:443-450, 2005
39. Shono K, Tajiri T, Fujii Y, et al: Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. J Pediatr Surg 35:1415-1420, 2000
40. Corrias MV, Parodi S, Haupt R, et al: Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. Br J Cancer 98:263-269, 2008